Istari Oncology, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2014-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
9
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors
- Conditions
- Solid TumorNon-muscle-invasive Bladder CancerBladder Cancer
- Interventions
- Other: 5% DDM
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Istari Oncology, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT04690699
- Locations
- 🇺🇸
Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
EAP for the Treatment of Glioblastoma With PVSRIPO
- Conditions
- Glioblastoma
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Istari Oncology, Inc.
- Registration Number
- NCT04599647
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
- Conditions
- Melanoma
- Interventions
- Biological: Anti-PD-1 Checkpoint Inhibitor
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Istari Oncology, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT04577807
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Orlando Health U7 Health Cancer Center, Orlando, Florida, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
- Conditions
- Supratentorial GlioblastomaBrain TumorGlioblastomaRecurrent Glioblastoma
- Interventions
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Istari Oncology, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04479241
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸UConn Health, Farmington, Connecticut, United States
🇺🇸Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States
PVSRIPO for Patients With Unresectable Melanoma
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Istari Oncology, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03712358
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
- Prev
- 1
- 2
- Next